TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29785466

Group type: EXPERIMENTAL
Intervention: Modified atWork intervention (MAW)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Original atWork intervention (OAW)
Number of subjects: 1011
Study: 29448828

Group type: EXPERIMENTAL
Intervention: Histidine‐tryptophan‐ketoglutarate with terminal warm blood cardioplegia
Number of subjects: 109

Group type: COMPARATOR
Intervention: Histidine‐tryptophan‐ketoglutarate only
Number of subjects: 109
Study: 26965932

Group type: EXPERIMENTAL
Intervention: Zotarolimus‐eluting Endeavor Sprint stent (E‐ZES)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Bare‐metal stent (BMS)
Number of subjects: 828
Study: 24485080

Group type: COMPARATOR
Intervention: 10 mL of gel of lidocaine 2% intrarectal with 50mg tramadol (2 tablets)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mL of lidocaine 2% injected at the level of periprostatics laterals and apical areas
Number of subjects: 60
Study: 22791802

Group type: EXPERIMENTAL
Intervention: Saline-based tetrastarch HES infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Balanced solution-based HES infusion
Number of subjects: 13
Study: 19712201

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis C patients (CHC group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 62
Study: 18060924

Group type: EXPERIMENTAL
Intervention: Dermal Thermometry Group
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard Therapy Group
Number of subjects: 225
Study: 15943224

Group type: EXPERIMENTAL
Intervention: 30 mg genistein
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 60 mg genistein
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 150 mg genistein
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 300 mg genistein
Number of subjects: 40
Study: 12847933

Group type: EXPERIMENTAL
Intervention: Face-to-face case management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telecommunication case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10435880

Group type: COMPARATOR
Intervention: Placebo plus GHRH (100 microg, i.v. in bolus)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg p.o.) before GHRH injection
Number of subjects: 14
Study: 10606109

Group type: EXPERIMENTAL
Intervention: MULTI-LINK DUET stents
Number of subjects: 270
Study: 2093422

Group type: EXPERIMENTAL
Intervention: Almitrine-raubasine
Number of subjects: 40
Study: 838992

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA), 50 mug four times daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA)
Number of subjects: 26
Study: 30904872

Group type: EXPERIMENTAL
Intervention: Group exercise intervention (exercise classes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 28741013

Group type: EXPERIMENTAL
Intervention: LUCAS CPR
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Early LUCAS CPR
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Late LUCAS CPR
Number of subjects: 1274
Study: 25305230

Group type: EXPERIMENTAL
Intervention: Prophylactic cloxacillin (2 g IV) or clindamycin (600 mg IV)
Number of subjects: 325

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 325
Study: 23874575

Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Self-administered therapy (SAT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both DAART and SAT
Number of subjects: 107
Study: 21267804

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 4.5 g i.v. (single-dose)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg or cotrimoxazol 960 mg i.v./p.o. (5 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (varied administration and duration of different antibiotics)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam group
Number of subjects: 51
Study: 19799843

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted whole-virus vaccine (45 microg)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted whole-virus vaccine (15 microg)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted whole-virus vaccine (5 microg)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Intradermal whole-virus vaccine
Number of subjects: 353

Group type: COMPARATOR
Intervention: Virosomal vaccine
Number of subjects: 353
Study: 16902841

Group type: EXPERIMENTAL
Intervention: Leg training on a cycle-ergometer for 45 min/day, 4 days/week for six weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Leg training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 14728939

Group type: EXPERIMENTAL
Intervention: Rectal bleeding
Number of subjects: 8507

Group type: EXPERIMENTAL
Intervention: Rectal bleeding with altered bowel habit
Number of subjects: 8507

Group type: EXPERIMENTAL
Intervention: Isolated rectal bleeding
Number of subjects: 8507
Study: 11297722

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 16)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 35
Study: 9106123

Group type: EXPERIMENTAL
Intervention: Selegiline (20 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7930698

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus genotype 1 (n = 38, subtypes 1a [27] and 1b [11])
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus genotypes 2a (n = 1), 2b (n = 3), 3a (n = 20), and 5a (n = 1)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Severe disease hemophiliacs
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Changes in circulating major genotype and serotype
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Change from one subtype to another
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Introduction of inactivated clotting factor
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Coinfected with human immunodeficiency virus
Number of subjects: 63
Study: 3794874

Group type: EXPERIMENTAL
Intervention: Single-dose gentamicin therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional treatment for 10 days
Number of subjects: 21
Study: 29970654

Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Open esophagectomy (OE)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Comprehensive Complication Index (CCI)
Number of subjects: 144
Study: 28282689

Group type: EXPERIMENTAL
Intervention: Water exchange
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Water immersion
Number of subjects: 1224
Study: 26213156

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 14
Study: 22502816

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy (ADT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy (ADT)
Number of subjects: 173
Study: 20546945

Group type: EXPERIMENTAL
Intervention: Xin-yi-san (XYS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 18164459

Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Number of subjects: 0
Study: 15899109

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25mg IV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Palonosetron 0.25mg IV with aprepitant 125 mg on day 1 and 80 mg on days 2 and 3
Number of subjects: 12

Group type: COMPARATOR
Intervention: Palonosetron 0.25mg IV with aprepitant
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25mg IV and palonosetron/aprepitant regimen
Number of subjects: 12
Study: 12559781

Group type: EXPERIMENTAL
Intervention: Structured antiviral drug treatment interruptions (STIs) with therapeutic HIV immunizations
Number of subjects: 25

Group type: COMPARATOR
Intervention: Structured antiviral drug treatment interruptions (STIs) without therapeutic HIV immunizations
Number of subjects: 25
Study: 10326816

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7574016

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 vol%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 vol%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 vol%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 2.0 vol%
Number of subjects: 12
Study: 1659189

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) administered orally twice daily at a total daily dose of 750 mg or 1,500 mg for 12 weeks
Number of subjects: 30
Study: 6992834

Group type: EXPERIMENTAL
Intervention: Aromatic retinoid (Ro 10‐9359) orally (0.50‐0.66 mg/kg body weight) and placebo cream topically
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aromatic retinoid (Ro 10‐9359) orally (0.50‐0.66 mg/kg body weight) with 0.1% triamcinolone acetonide and 5% salicylic acid in lanette wax cream
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo capsules with 0.1% triamcinolone acetonide and 5% salicylic acid in lanette wax cream
Number of subjects: 90
Study: 30745183

Group type: EXPERIMENTAL
Intervention: Psychoeducational therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 84
Study: 30742122

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 35

Group type: COMPARATOR
Intervention: Adjuvant PD-1 blockade alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 blockade
Number of subjects: 35

Group type: COMPARATOR
Intervention: Adjuvant therapy alone
Number of subjects: 35
Study: 28935077

Group type: EXPERIMENTAL
Intervention: Absorb BVS implantation
Number of subjects: 505
Study: 26611191

Group type: EXPERIMENTAL
Intervention: Midwife-performed cervical length measurement (CLM) after training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Obstetrician-performed CLM
Number of subjects: 65
Study: 23499440

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks (cohort A)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg plus peginterferon and ribavirin for 24 weeks (cohort B)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 12 weeks of sofosbuvir plus peginterferon and ribavirin followed by 12 weeks of either sofosbuvir monotherapy or sofosbuvir plus ribavirin (cohort C)
Number of subjects: 316
Study: 21194997

Group type: EXPERIMENTAL
Intervention: Distraction condition (playing video games during heat-capsaicin pain)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pain only condition (heat and capsaicin application)
Number of subjects: 28
Study: 19288973

Group type: EXPERIMENTAL
Intervention: Chronic FVPD consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute FVPD consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugar-matched control
Number of subjects: 0
Study: 16758944

Group type: EXPERIMENTAL
Intervention: HHD with 6% hydroxyethyl starch (HES) 130/0.4 solution, 15 ml/kg before anesthesia and 33 ml/kg intraoperatively
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group receiving no preoperative HHD
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HHD group
Number of subjects: 80
Study: 15089784

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11274311

Group type: EXPERIMENTAL
Intervention: Recent infection by Campylobacter jejuni
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Recent infection by cytomegalovirus
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Recent infection by Epstein-Barr virus
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Inexcitable nerves
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 229
Study: 9278199

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trandolapril with Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8350363

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily for 2 or 5 years)
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years)
Number of subjects: 2365

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2365
Study: 3784458

Group type: EXPERIMENTAL
Intervention: Healthy overweight subjects
Number of subjects: 639

Group type: COMPARATOR
Intervention: Healthy subjects (not specified if overweight or not)
Number of subjects: 639
Study: 30613054

Group type: EXPERIMENTAL
Intervention: Combined exercise program (60 minutes) and TTM based strategies (10 minutes) for 12 weeks (36 sessions)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 43
Study: 26951208

Group type: EXPERIMENTAL
Intervention: Edoxaban, with a 50% dose reduction in patients with low body weight (≤60 kg), moderate renal impairment (CLCR ≤50 mL/min), or concomitant P-glycoprotein inhibitors.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Edoxaban without specified dose reduction.
Number of subjects: 0
Study: 24763663

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with MRI-detected skull-base invasion classification
Number of subjects: 749
Study: 22574572

Group type: EXPERIMENTAL
Intervention: Variable-frequency electroacupuncture (EA) combined with herbal-moxa moxibustion (15 cm roll, components include corydalis tuber, astragali radix, myrrh, etc.), applied to Jiaji (EX-B 2) and Ashi-point, once daily for 7 days.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Brufen (0.3 g, b.i.d.), vitamin B1 (10 mg, t.i.d.), vitamin E (100 mg, b.i.d.)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups received treatment and assessed using the visual analog scale (VAS) for pain reaction.
Number of subjects: 37
Study: 19661237

Group type: EXPERIMENTAL
Intervention: Flexible VA-guided regimen after three initial injections of ranibizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly and quarterly VA-guided regimens
Number of subjects: 0
Study: 16640798

Group type: EXPERIMENTAL
Intervention: Fast Improvement cluster
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Worsening cluster
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Fast Improvement and Worsening clusters
Number of subjects: 230

Group type: COMPARATOR
Intervention: Steady or Fluctuating clusters
Number of subjects: 230
Study: 15262458

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/d with diet (S-D)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 299
Study: 11435511

Group type: EXPERIMENTAL
Intervention: Diet rich in plant sterols (replacing milk fat with vegetable fat)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet with small amounts of plant sterols
Number of subjects: 40
Study: 9151289

Group type: EXPERIMENTAL
Intervention: 1.5 g of acetaminophen (oral dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zidovudine treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enzyme inducers (rifampicin or phenytoin)
Number of subjects: 60
Study: 8292548

Group type: EXPERIMENTAL
Intervention: Self-worth protective students in achievement situations
Number of subjects: 0
Study: 3304479

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) alone for 4 months followed by chemotherapy + TAM
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) + chemotherapy simultaneously
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone for 8 months followed by TAM + chemotherapy
Number of subjects: 247
Study: 29951915

Group type: EXPERIMENTAL
Intervention: R-training (endurance training with blood flow restriction)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NR-training (endurance training in free-flow condition)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (C)
Number of subjects: 10
Study: 26995096

Group type: EXPERIMENTAL
Intervention: Coffee, whey protein, inulin, and dextrin (group S)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Inulin-enriched beverage (group I)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control beverage - coffee alone (group C)
Number of subjects: 269
Study: 25221948

Group type: EXPERIMENTAL
Intervention: BMI ≥25 kg/m2 in men
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Raised waist circumference (WC) in men
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: BMI ≥25 kg/m2 in women
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Raised waist circumference (WC) in women
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: BMI ≥25 kg/m2 in men (comparison between 1990 and 2008/09)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: BMI ≥25 kg/m2 in women (comparison between 1990 and 2008/09)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Associations with higher BMI in men
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Associations with higher BMI in women
Number of subjects: 1099
Study: 22050362

Group type: EXPERIMENTAL
Intervention: Structured programme (home training programme with ergonomic advice, wrist supports, and/or night bandages)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Corticosteroid injections
Number of subjects: 297

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 297
Study: 20480132

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18759640

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Clozapine (after switching from olanzapine)
Number of subjects: 39
Study: 15682246

Group type: EXPERIMENTAL
Intervention: Community-based health promotion activities
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control area (no health promotion activities during the trial)
Number of subjects: 4000
Study: 15256232

Group type: EXPERIMENTAL
Intervention: Early removal of the axillary drain (24 hours postoperatively)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Keeping the drain in until discharge had decreased to less than 40 ml/24 h
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Preservation of the pectoral fascia
Number of subjects: 247

Group type: COMPARATOR
Intervention: Removal of the pectoral fascia
Number of subjects: 247
Study: 11551574

Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol orally
Number of subjects: 9264

Group type: COMPARATOR
Intervention: 10 IU oxytocin intravenously or intramuscularly
Number of subjects: 9264
Study: 9362160

Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN α)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Standard chemotherapy (hydroxyurea or busulfan)
Number of subjects: 1554
Study: 8489836

Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mg I/ml
Number of subjects: 59

Group type: COMPARATOR
Intervention: Iohexol 300 mg I/ml
Number of subjects: 59
Study: 3320229

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 356

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Enflurane (in group with three conceptuses)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Halothane (in group with three conceptuses)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Both anesthetic agents
Number of subjects: 356
Study: 28834259

Group type: EXPERIMENTAL
Intervention: Golimumab (tumor necrosis factor inhibitor), dosage not specified, duration 24 weeks
Number of subjects: 0
Study: 26291335

Group type: EXPERIMENTAL
Intervention: Vilazodone (20-40 mg/day)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 395
Study: 24206796

Group type: EXPERIMENTAL
Intervention: Letter with information about latent TB and the PPD test
Number of subjects: 293

Group type: COMPARATOR
Intervention: Regular letter (control group)
Number of subjects: 293
Study: 21188521

Group type: EXPERIMENTAL
Intervention: Vitamin K1 (oral daily dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vitamin K1 (intravenous weekly doses)
Number of subjects: 27
Study: 18334913

Group type: EXPERIMENTAL
Intervention: APOE epsilon4 and BCHE-K alleles
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 464
Study: 17153647

Group type: EXPERIMENTAL
Intervention: CHX/F mouthrinse
Number of subjects: 24

Group type: COMPARATOR
Intervention: CHX mouthrinse
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 24
Study: 14610140

Group type: EXPERIMENTAL
Intervention: Interferon beta 1a (IFN[beta]‐1a)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10901114

Group type: EXPERIMENTAL
Intervention: n-butyl acetate at 12 ppm (44 or 56 mg/m3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: n-butyl acetate at 48 ppm (180 or 228 mg/m3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: toluene at 12 ppm (44 or 56 mg/m3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: toluene at 48 ppm (180 or 228 mg/m3)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clean air baseline conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Digit symbol test of the Wechsler Adult Intelligence Scale
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Complex reaction-time task
Number of subjects: 36
Study: 8929726

Group type: EXPERIMENTAL
Intervention: DTPw-HB vaccine administered according to a 0, 1.5, 3-month schedule
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DTPw-HB vaccine
Number of subjects: 120
Study: 1424851

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham training (control group)
Number of subjects: 30